OBJECTIVE: To assess the potential impact over 10 years of a partially effective HIV vaccine in a cohort of 15-year-old adolescent girls in South Africa in terms of HIV infections and deaths prevented in mothers and infants. METHODS: A computer simulation was constructed using a population of all 15-year-old adolescent girls in South Africa followed for 10 years. A partially effective vaccine is introduced into this population with the ability to reduce the HIV incidence rates of the adolescents and vertical transmission to their infants through birth and breast-feeding. At the end of this 10 year period, the number of HIV infections and death prevented in adolescents and infants is analyzed. RESULTS: Using a 5% HIV incidence rate, a 50% effective vaccine decreases the number of HIV cases among adolescents by 57,653 (28.7%) and the number of cases among infants by 13,765 (28.9%) over 10 years. In addition, assuming a vaccine cost of $20 per dose, the vaccination program can save approximately $120 million for the South African government over 10 years. CONCLUSION: A partially effective HIV vaccine has an important role in HIV prevention in adolescents and infants in South Africa irrespective of other public policy implementations.
OBJECTIVE: To assess the potential impact over 10 years of a partially effective HIV vaccine in a cohort of 15-year-old adolescent girls in South Africa in terms of HIV infections and deaths prevented in mothers and infants. METHODS: A computer simulation was constructed using a population of all 15-year-old adolescent girls in South Africa followed for 10 years. A partially effective vaccine is introduced into this population with the ability to reduce the HIV incidence rates of the adolescents and vertical transmission to their infants through birth and breast-feeding. At the end of this 10 year period, the number of HIV infections and death prevented in adolescents and infants is analyzed. RESULTS: Using a 5% HIV incidence rate, a 50% effective vaccine decreases the number of HIV cases among adolescents by 57,653 (28.7%) and the number of cases among infants by 13,765 (28.9%) over 10 years. In addition, assuming a vaccine cost of $20 per dose, the vaccination program can save approximately $120 million for the South African government over 10 years. CONCLUSION: A partially effective HIV vaccine has an important role in HIV prevention in adolescents and infants in South Africa irrespective of other public policy implementations.
Authors: Ouzama Nicholson; Fay DiCandilo; James Kublin; Xiao Sun; Erin Quirk; Michelle Miller; Glenda Gray; Jean Pape; Michael N Robertson; Devan V Mehrotra; Steven Self; Katherine Turner; Jorge Sanchez; Punnee Pitisuttithum; Ann Duerr; Sheri Dubey; Lisa Kierstead; Danilo Casimiro; Scott M Hammer For The Merck V/Hiv Vaccine Trials Network Study Team Journal: AIDS Res Hum Retroviruses Date: 2010-11-23 Impact factor: 2.205
Authors: Kyeen M Andersson; Douglas K Owens; Eftyhia Vardas; Glenda E Gray; James A McIntyre; A David Paltiel Journal: J Acquir Immune Defic Syndr Date: 2007-09-01 Impact factor: 3.731
Authors: Joshua T Herbeck; Kathryn Peebles; Paul T Edlefsen; Morgane Rolland; James T Murphy; Geoffrey S Gottlieb; Neil Abernethy; James I Mullins; John E Mittler; Steven M Goodreau Journal: Vaccine Date: 2017-12-11 Impact factor: 3.641
Authors: Lori L Heise; Charlotte Watts; Anna Foss; James Trussell; Peter Vickerman; Richard Hayes; Sheena McCormack Journal: Contraception Date: 2010-08-07 Impact factor: 3.375
Authors: L A Lagenaur; B E Sanders-Beer; B Brichacek; R Pal; X Liu; Y Liu; R Yu; D Venzon; P P Lee; D H Hamer Journal: Mucosal Immunol Date: 2011-07-06 Impact factor: 7.313
Authors: Gabriel Catano; Hemant Kulkarni; Weijing He; Vincent C Marconi; Brian K Agan; Michael Landrum; Stephanie Anderson; Judith Delmar; Vanessa Telles; Li Song; John Castiblanco; Robert A Clark; Matthew J Dolan; Sunil K Ahuja Journal: PLoS One Date: 2008-11-04 Impact factor: 3.240
Authors: Hemant Kulkarni; Vincent C Marconi; Brian K Agan; Carole McArthur; George Crawford; Robert A Clark; Matthew J Dolan; Sunil K Ahuja Journal: PLoS One Date: 2008-11-07 Impact factor: 3.240